These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17090868)

  • 1. Gastric adenocarcinoma presenting with intestinal pseudoobstruction, successfully treated with octreotide.
    Sharma S; Ghoshal UC; Bhat G; Choudhuri G
    Indian J Med Sci; 2006 Nov; 60(11):467-70. PubMed ID: 17090868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide treatment for paraneoplastic intestinal pseudo-obstruction complicating SCLC.
    Sørhaug S; Steinshamn SL; Waldum HL
    Lung Cancer; 2005 Apr; 48(1):137-40. PubMed ID: 15777981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction.
    Verne GN; Eaker EY; Hardy E; Sninsky CA
    Dig Dis Sci; 1995 Sep; 40(9):1892-901. PubMed ID: 7555439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic intestinal pseudoobstruction: report of four pediatric patients.
    Dalgiç B; Sari S; Doğan I; Unal S
    Turk J Gastroenterol; 2005 Jun; 16(2):93-7. PubMed ID: 16252200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to octreotide of intestinal pseudoobstruction and pneumatosis cystoides intestinalis associated with progressive systemic sclerosis.
    Kobayashi T; Kobayashi M; Naka M; Nakajima K; Momose A; Toi M
    Intern Med; 1993 Jul; 32(7):607-9. PubMed ID: 8286845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Small bowel pseudo-obstruction revealing an early scleroderma. Long-term efficacy of octreotide and erythromycin].
    Lecomte T; Cavicchi M; Delchier JC
    Gastroenterol Clin Biol; 2000 Mar; 24(3):361-3. PubMed ID: 10804347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide for palliative treatment of bleeding from unresectable gastric cancer.
    Sanaka M; Yamamoto T; Kawakami T; Kuyama Y
    Hepatogastroenterology; 2005; 52(64):2 p preceding I. PubMed ID: 16001612
    [No Abstract]   [Full Text] [Related]  

  • 8. Octreotide acetate successfully treated a bowel obstruction caused by peritoneally disseminated gastric cancer, thereby enabling the subsequent use of oral S-1 chemotherapy.
    Kumagai K; Saikawa Y; Fukuda K; Ito R; Igarashi T; Tsuwano S; Nakamura R; Takahashi T; Takeuchi H; Kitagawa Y
    Int J Clin Oncol; 2009 Aug; 14(4):372-5. PubMed ID: 19705252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulins and octreotide as treatment of intestinal pseudo-obstruction revealing a recurrence of polymyositis.
    Marie I; Kerleau JM; Ducrotte P; Denis P; Maillot C; Levesque H; Courtois H
    Rheumatology (Oxford); 2001 Sep; 40(9):1072-3. PubMed ID: 11561127
    [No Abstract]   [Full Text] [Related]  

  • 10. Radiological imaging change in a malignant bowel obstruction patient treated with octreotide.
    Shinjo T; Kagami R
    Support Care Cancer; 2009 Jun; 17(6):753-5. PubMed ID: 19277723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to use octreotide for malignant bowel obstruction.
    Ripamonti C; Mercadante S
    J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519
    [No Abstract]   [Full Text] [Related]  

  • 12. Octreotide in malignant intestinal obstruction.
    Pandha HS; Waxman J
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():5-10. PubMed ID: 8822079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
    Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
    Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin and hepatocellular carcinoma.
    Kapadia CR
    Gastroenterology; 1998 Nov; 115(5):1298-9. PubMed ID: 9797392
    [No Abstract]   [Full Text] [Related]  

  • 15. Octreotide.
    Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ
    N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003
    [No Abstract]   [Full Text] [Related]  

  • 16. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of bronchorrhea with octreotide in a patient with adenocarcinoma of the lung.
    Hudson E; Lester JF; Attanoos RL; Linnane SJ; Byrne A
    J Pain Symptom Manage; 2006 Sep; 32(3):200-2. PubMed ID: 16939841
    [No Abstract]   [Full Text] [Related]  

  • 18. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases.
    Perlemuter G; Cacoub P; Chaussade S; Wechsler B; Couturier D; Piette JC
    Arthritis Rheum; 1999 Jul; 42(7):1545-9. PubMed ID: 10403284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe intestinal pseudoobstruction in a patient with systemic sclerosis. Successful treatment with octreotide.
    Lanting PJ; Kruijsen MW; Rasher JJ; van den Hoogen FH; Boerbooms AM; van de Putte LB
    J Rheumatol; 1993 Dec; 20(12):2175. PubMed ID: 8014959
    [No Abstract]   [Full Text] [Related]  

  • 20. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
    Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
    Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.